Related Experiment Video
Updated: Aug 6, 2026

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
Published on: December 16, 2022
Dependence on Cardiac Contractility Modulation Therapy: Loss of Continuous and Effective Modulation as a Cause of
Krzysztof Kaczmarek1, Adam Wojtaszczyk1, Pawel Ptaszynski1
1Department of Electrocardiology, Medical University of Lodz, Lodz, POL.
Insights
Cardiac contractility modulation (CCM) therapy can improve heart failure symptoms. Lead failures can disrupt CCM, necessitating lead replacement for sustained patient benefit and device integrity.
Area of Science:
- Cardiology
- Biomedical Engineering
Background:
- Cardiac contractility modulation (CCM) offers a device-based therapy for heart failure patients with reduced ejection fraction (LVEF) unsuitable for cardiac resynchronization therapy.
- CCM utilizes non-excitatory electrical impulses during the myocardial refractory period to enhance contractility without increasing oxygen demand.
Abstract:
Cardiac contractility modulation (CCM) is a device-based therapy for patients with heart failure, reduced left ventricular ejection fraction (LVEF), and narrow QRS who are not candidates for cardiac resynchronization therapy. CCM delivers non-excitatory impulses during the absolute refractory period, improving myocardial contractility without increasing oxygen consumption. We report a 58-year-old man with dilated cardiomyopathy and persistent New York Heart Association (NYHA) class III symptoms despite optimal therapy who underwent CCM implantation. The patient initially showed significant clinical improvement, with increased LVEF and functional status. However, several years later, he developed clinical deterioration associated with intermittent loss of effective CCM delivery. Surgical revision revealed insulation defects in all three leads, likely due to mechanical interactions. Lead replacement restored CCM function, resulting in marked and sustained improvement in exercise capacity, LVEF, and N-terminal pro B-type natriuretic peptide over long-term follow-up. This case highlights the importance of continuous and effective CCM delivery, as well as the need for careful long-term monitoring of device integrity, particularly in patients with multiple intracardiac leads.
Related Concept Videos
Pathophysiology of Heart Failure
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Heart Failure I: Introduction
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Cardiomyopathy II: Dilated Cardiomyopathy
